In a study by Pekker et al. (2022), in 2022, the Agilent Resolution ctDx FIRST successfully identified KRAS G12C variants from collected NSCLC plasma samples without showing any false positives in samples from healthy donors. Here, KRAS is linked to non-small cell lung carcinoma.